| Name | Title | Contact Details |
|---|
WE ARE A DESIGN COMPANY. Allovus is a woman-owned equal opportunity employer committed to fostering an inclusive and creative environment. Our employees produce meaningful work, create strong community connections, and inspire delight in our clients. Studio Our skilled and collaborative Design Studio team provides beautiful, elegant, and functional solutions for our clients. No matter the creative challenge, our intentionally small and agile team operates as a one-stop design shop. Custom Solutions Deliverable based teams, managed for you. In todays world, many of our clients are looking for ways to augment their own teams with creative talent in different ways outside the typical individual contractor approach. Our ability to build, nurture, and employ teams of people is one of our strongest attributes as an organization. Were excited to provide a model to our clients which allows you to retain a world-class team, while meeting the compliance standards of your organization, all while delivering amazing designs on time and on budget. Search We specialize in permanent placement using a holistic, qualitative approach to make the perfect match.
With a history spanning more than 145 years, Columbus McKinnon has become a global leader in intelligent motion solutions. Our high-quality brands, such as CM®, STAHL CraneSystems®, Yale®, Magnetek®, Coffing® Hoists, Dorner®, and Duff-Norton®, work together to move the world forward and improve lives. Whether its increasing safety or improving productivity, our intelligent motion technology is hard at work worldwide.
9to5 Seating is a vertically-integrated, privately owned company, founded in 1986, which specializes in the design and production of ergonomic office seating to accommodate the rigorous demands of todays office environments. 9to5 Seating presents an extensive collection of executive, task, guest, conference, stool and lounge seating. Customization is an everyday demand that 9to5 Seating welcomes; seats, controls, arms, chair adjustments, finishes, and upholstery options are plentiful. 9to5 Seating combines its state-of-the-art, in-house manufacturing systems with a commitment to continuous improvements in all phases of the operation. With over 500,000 sq. ft. of manufacturing resources, we are confidently empowered to deliver products offered at unparalleled pricing, with quality built into every phase of manufacturing. Our dedication to becoming the leader in office furniture requires that we go beyond customer expectations. We strive to provide quality products, plethora of upholstery options, express shipping superior customer service and the best warranty as possible.
Somos una empresa internacional especializada en startups y empresas tech de LATAM. Acompañamos el crecimiento acelerado de los founders garantizándoles en cada etapa el cumplimiento de todos sus compromisos financieros, contables, impositivos y legales en cada país en el que operan. Nuestras soluciones contemplan servicios de compliance, impuestos internacionales, softlanding, CFO Services, transaction services y legal services. Nos caracterizamos por nuestra velocidad de respuesta, profesionalismo y calidad en la ejecución.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.